Mary Kay Ladone - Jun 16, 2022 Form 4 Insider Report for Bioventus Inc. (BVS)

Role: Director
Signature: /s/ Anthony D'Adamio, Attorney-in-Fact
Stock symbol: BVS
Transactions as of: Jun 16, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/22/2022, 08:39 PM
Previous filing: Jun 10, 2022
Next filing: Jun 2, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BVS	Class A common stock	Options Exercise	$0	+1.81K		$0.00	1.81K	Jun 16, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BVS	Restricted Stock Units	Options Exercise	$0	-1.81K	-33.33%	$0.00	3.63K	Jun 16, 2022	Class A Common Stock	1.81K		Direct	F1, F2
transaction	BVS	Restricted Stock Units	Award	$0	+16.6K		$0.00	16.6K	Jun 17, 2022	Class A Common Stock	16.6K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2	The remaining RSUs shall vest and become exercisable in two approximately equal installments on June 16, 2023 and June 16, 2024, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date.
F3	The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date.